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REVIEW
LEPROSY NEPHROPATHY: A REVIEW OF CLINICAL AND HISTOPATHOLOGICAL FEATURES
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SUMMARY
Leprosy is a chronic disease caused by Mycobacterium leprae, highly incapacitating, and with systemic involvement in some 
cases. Renal involvement has been reported in all forms of the disease, and it is more frequent in multibacillary forms. The clinical 
presentation is variable and is determined by the host immunologic system reaction to the bacilli. During the course of the disease 
there are the so called reactional states, in which the immune system reacts against the bacilli, exacerbating the clinical manifestations. 
Different renal lesions have been described in leprosy, including acute and chronic glomerulonephritis, interstitial nephritis, secondary 
amyloidosis and pyelonephritis. The exact mechanism that leads to glomerulonephritis in leprosy is not completely understood. 
Leprosy treatment includes rifampicin, dapsone and clofazimine. Prednisone and non-steroidal anti-inflammatory drugs may be used 
to control acute immunological episodes.
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INTRODUCTION
Leprosy is a chronic disease caused by Mycobacterium leprae, an 
acid-fast bacilli, intracellular parasite, with predilection to Schwann cell 
and skin. The disease is highly incapacitating, and systemic involvement 
is reported in some cases45. Renal involvement has been reported in all 
forms of the disease, and it is more frequent in multibacillary forms51. 
The present paper presents a review of the clinical and histopathological 
aspects of leprosy nephropathy.
EPIDEMIOLOGY: The number of leprosy patients is estimated to 
be between 10 and 15 million, distributed across more than 100 countries. 
In 2007, a total of 254,525 new cases were reported all over the world45. 
Brazil is considered as having a high endemicity index and is the country 
with the second highest number of cases, with 37,610 new cases registered 
in 200958. Leprosy prevalence in Brazil was reduced by 85%, going from 
17 to 3.8 cases/10,000 population in the period between 1985 and 200135. 
LEPROSY PATHOPHYSIOLOGY: Infected persons with M. 
leprae are thought not to develop clinical disease. M. leprae is slow 
growing and the incubation period is long at 2-12 years. The M. leprae 
has a high infective power, but low pathogenic power3. Person-to-person 
spread via nasal droplets is believed to be the main route of leprosy 
transmission. Most people with leprosy are non-infectious. Patients 
with lepromatous leprosy excrete M. leprae from their nasal mucosa 
and skin and are infectious before starting treatment with multidrug 
therapy. Contacts of these patients are, therefore, at increased risk of 
developing the disease. There may be a genetic predisposition to disease 
manifestation. Infection with M. leprae leads to chronic granulomatous 
inflammation in skin and peripheral nerves46. Single-nucleotide 
polymorphism (SNP) association studies showed a low lymphotoxin-α 
(LTA)-producing allele as a major genetic risk factor for early onset 
leprosy. Other SNPs to be associated with disease and/or the development 
of reactions in several genes, such as vitamin D receptor (VDR), TNF-α, 
IL-10, IFN-γ, HLA genes, and TLR1 have also been suggested6. The type 
of leprosy that patients develop is determined by their cell-mediated 
immune response to infection. Patients with tuberculoid disease have a 
good cell-mediated immune response and few lesions with no detectable 
mycobacteria. Patients with lepromatous leprosy are anergic towards M. 
leprae and have multiple lesions with mycobacteria present46. Schwann 
cells (SCs) are a major target for infection by M. leprae leading to 
nerve injury, demyelination, and consequent disability. Binding of M. 
leprae to SCs induces demyelination and loss of axonal conductance. 
Macrophages are one of the most abundant host cells to come in contact 
with mycobacteria. Phagocytosis of M. leprae by monocyte-derived 
macrophages can be mediated by complement receptors CR1 (CD35), 
CR3 (CD11b/CD18), and CR4 (CD11c/CD18) and is regulated by protein 
kinase6. The inflammation present in nerves is driven by mycobacterial 
antigens that activate a destructive inflammatory immune response 
mediated by CD4+ cells and macrophages, and with involvement of 
multiple pro-inflammatory cytokines, such as tumor necrosis factor α46. 
In the tuberculoid lesions there is a predominance of CD4+ auxiliary 
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T cells and Th1 cytokines such as IL-2 and IFN-gamma, while in 
lepromatous (Virchowian) lesions suppressant T cells, CD8+, and Th2 
cytokines such as IL-4, IL-5 and IL-103 predominate. In the tuberculoid 
type, the exacerbation of cellular immunity and the production of 
pro-inflammatory cytokines (IL-1 and TNF-alpha) prevents the bacilli 
proliferation, but can cause injury to the host due to the lack of regulator 
factors. In the Virchowian type, the production of PGL-1 (phenolic 
glycolipid antigen-1) and LAM (lipoarabinomannan) antigens by the 
bacilli, inside macrophages, favors the escapade of the bacilli from the 
intramacrophage oxidation, because these antigens have a suppressant 
effect over macrophage activity, and then favors bacilli proliferation3.
CLINICAL MANIFESTATIONS: Leprosy is characterized by 
tegumentary lesions and nervous system injury. The clinical presentation 
is variable and is determined by the host immunologic system reaction 
to the bacilli. During the course of the disease there are the so called 
reactional states, in which the immune system reacts against the 
bacilli, exacerbating the clinical manifestations. There are two types 
of reactional states: reversal reaction (type I), which is more common 
in the paucibacillary forms, and erythema nodosum (type II), more 
common in multibacillary forms45. The disease is divided into four forms, 
according to the criteria established by the World Health Organization: 
indeterminate, tuberculoid, dimorphous and virchowian. The diagnosis 
and classification are based on clinical findings and complementary tests, 
such as baciloscopy, which allow the classification in multibacillary and 
paucibacillary.
EFFECTS OF IMMUNOSUPPRESSION, HIV AND 
TRANSPLANT IN LEPROSY: At the beginning of the HIV epidemic 
there was a fear that HIV infection could increase the risk of leprosy 
development or that the co-infection (HIV-leprosy) would cause a more 
severe disease46. This hypothesis was not confirmed, since some studies 
have shown that patients receiving highly active antiretroviral therapy are 
more likely to develop borderline tuberculoid leprosy than other types of 
leprosy46. HIV infection has not been reported to increase susceptibility to 
leprosy, impact on immune response to M. leprae, or to have a significant 
effect on the pathogenesis of neural or skin lesions to date. The initiation 
of antiretroviral treatment has been reported to be associated with 
activation of subclinical M. leprae infection and exacerbation of existing 
leprosy lesions (type I reaction) likely as part of immune reconstitution 
inflammatory syndrome6. Leprosy has also been reported to occur after 
organ transplantations, but this is not frequent and immunosuppressant 
therapy did not seem to affect the course of leprosy manifestations4,55. 
The course of leprosy seems not to be affected by immunosuppression55.
RENAL INVOLVEMENT: Renal involvement in leprosy was 
first described in the beginning of the XX century, through necropsy 
studies, in which glomerulonephritis and tubulointerstitial lesions were 
described28,36. Different renal lesions have been described in leprosy, 
including acute and chronic glomerulonephritis, interstitial nephritis, 
secondary amyloidosis and pyelonephritis19,41,48. There are several reports 
of renal involvement in leprosy, as summarized in Table 1.
The exact mechanism that leads to glomerulonephritis in leprosy 
is not completely understood. The M. leprae may be directly involved 
in renal injury and it has already been detected in glomeruli of infected 
patients. The glomerular lesion is probably caused by immunologic 
mechanism, with complement decrease and immune complexes 
deposition in glomerular basement membrane, subendothelial and 
subepithelial space, detected by electronic microscopy19,41,48. Some studies 
have also detected mesangial proliferation and the presence of IgA in the 
mesangial area53. The pathophysiology of renal involvement in leprosy 
is illustrated in Fig. 1.
A consistent relation between the lepromatous form, erythema 
nodosum and kidney disease has been described in some studies18. Although 
leprosy nephropathy is more frequent in the multibacillary form, it can also 
occur in other forms and in the absence of the reactional state19. 
A large retrospective study with 923 leprosy patients followed in a 
tertiary hospital in Brazil found acute kidney injury in 3.8% of cases, and 
65% of them had the multibacillary form. Risk factors for kidney injury 
were reactional state, multibacillary classification and advanced age10.
RENAL LESION MECHANISM: Erythema nodosum leprosum 
is a reactional state characterized by immune complexes formation in 
circulation and subsequent deposition in vessels and tissues. Sometimes 
they are determined by Hansen’s bacilli antigens which are released into 
circulation after the beginning of antibiotic therapy9. The antigens are 
recognized by host antibodies, and then immune complexes are formed. 
After this, immune complexes can deposit in the glomerulus or can 
occur by the formation of immune complexes in situ. However, not all 
glomerulonephritis in leprosy are associated with erythema nodosum, 
which raises the hypothesis of multifactorial influence in the development 
of leprosy nephropathy. In the virchowian form there is a cellular 
immunity decrease and a hyperactivation of humoral immunity, which 
makes the patient susceptible to the formation of immune complexes30.
The antigen that can induce the formation of immune complexes 
can originate from Hansen’s bacilli or even from therapeutic agents. 
Anti-dapsone antibodies have been detected in the circulation of leprosy 
patients. Auto-antibodies have also been described in leprosy, mainly 
cryoglobulins with IgG and IgM13.
Some patients with lower limb ulcers and secondary infections by 
Streptococcus presented a higher frequency of glomerulonephritis7. 
URINARY FINDINGS: Hematuria has been described in leprosy, 
mainly in the virchowian form and during erythema nodosum state, even 
in the absence of evident glomerulonephritis18. Microscopic hematuria 
is found in 12-16% of cases, which is higher than what is found in the 
general population (0.5-2%)7,17,57. This complication can disappear after 
a few months of specific treatment9. 
Proteinuria has been described in several studies and its prevalence 
varies from 2.1 to 68%, and it is also more frequent in the multibacillary 
forms7,27,29,39,50. Proteinuria varies from 0.4 to 8.9g/day. Nephrotic 
syndrome is not frequent in leprosy. RAMANUJAM et al.44 reported 
five cases in the virchowian form, four were in reactional state and only 
two had amyloid deposits detected.
Other urinary abnormalities, such as cylindruria and leukocyturia, 
are more frequently found in the virchowian form with reactional state. 
In the milder forms these abnormalities are uncommon44.
GLOMERULONEPHRITIS: Glomerulonephritis represents the 
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most frequent type of kidney disease in leprosy. In renal biopsy studies 
glomerulonephritis was found in more than 30% of patients30, which is 
higher than what is found in necropsy studies (7%)13. In the multibacillary 
form, the prevalence of glomerulonephritis is higher8. Erythema nodosum 
has a strong correlation with the occurrence of glomerulonephritis, 
although there are some reports of its occurrence in reactional state 
type I7,9. Almost all kinds of glomerulonephritis have been described in 
leprosy7,13, and there is no specific histopathological pattern in leprosy 
nephropathy. There is a discrete predominance of membranoproliferative 
glomerulonephritis, which are in general associated with infectious 
disease-associated nephropathies20,24,42,49.
HISTOPATHOLOGICAL FINDINGS: The diversity of 
histopathological lesions found in leprosy suggests a heterogeneous 
Table 1
Studies and case reports on kidney involvement in leprosy 
     
Reference Number of 
cases
Age (years) Gender Clinical picture Kidney biopsy
Iveson (1975)23 1 19 M Poliarthritis AKI Diffuse proliferative lesion
Date (1977)12 19 Proteinuria Hematuria
Diffuse proliferative lesion 
Amyloidosis
Singhal (1977)53 3 AKI Acute tubular necrosis Crescentic nephropathy 
Gupta (1981)20 21 Diffuse proliferative lesion Amyloidosis
Phadnis (1982)42 50
Membranoproliferative nephropathy 
Membranous nephropathy 
Amyloidosis
Chugh (1983)7 60
Proteinuria 
Hematuria 
AKI
Mesangial proliferative lesion (8.3%) 
Diffuse proliferative lesion (8.3%) 
Amyloidosis (5%)
Jayalakshmi (1987)25 35 74 AKI Interstitial nephritis Amyloidosis
Al-Mohaya (1988)2 1 17 M Proteinuria Membranoproliferative nephropathy
Madiwale (1994)34 2 30-45 M Proteinuria Hematuria Crescentic nephropathy
Ahsan (1995)1 1 79 M Hematuria AKI Diffuse proliferative lesion
Lau (1995)31 1 71 M AKI Drug hepatitis Interstitial nephritis
Nakayama (2001)38 199 47-74 M (79.3%)
Amyloidosis (31%) 
Diffuse proliferative lesion (5%); 
Focal proliferative (4%); 
Membranoproliferative (2%); 
Membranous (1%); 
Mesangial proliferative lesion (0.5%) 
Glomerular sclerosis (11%) 
Tubulo-interstitial nephritis (9%) 
Granulomata (1%)
Oliveira (2008)40 59 43 ± 15 M (51%)
Concentration defect (84%) 
Acidification defect (30%) 
Function loss (50%)
No
Sharma (2010)49 1 25 F AKI Proteinuria Crescentic nephropathy
Silva Junior (2010)52 1 58 M CKD AA Amyloidosis
Daher (2011)10 923 41 ± 19 M (53.3%)
Proteinuria (4.8%) 
Hematuria (6.8%) 
Function loss (3.8%)
No
M: Male; AKI: Acute kidney injury; CKD: Chronic kidney disease.
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disease  but  not  necessar i ly  wi th  d i ffe rent  e t io logies13. 
Immunohistochemical studies with renal tissue have identified the 
presence of granular deposits of IgG and C3, and less frequently IgA, 
IgM and fibrin in the mesangium and in the glomerular capillaries, 
which is characterized by immune complex deposits or in situ formation. 
Electronic microscopy confirms the presence of dense granular deposits 
in mesangial-subendothelial and subepithelial regions14,26. Complement 
consumption in some cases reinforces the hypothesis of an immune 
complex-mediated disease30.
A study by GROVER et al.19, with 72 leprosy patients undergoing 
renal biopsy found the following histopathological patterns: membranous 
nephropathy (31.5%) and mesangioproliferative glomerulonephritis 
(11.1%). VALLÉS et al.56 reported one case of IgA nephropathy in a patient 
with the virchowian form, with reduction in glomerular filtration rate.
Several renal biopsy studies have been performed in leprosy. JOHNY 
et al.26 performed renal biopsies in 35 patients with leprosy and identified 
histological abnormalities in 45% of them, and the most frequent was 
proliferative glomerulonephritis. GUPTA et al.20 performed renal 
biopsies in 21 patients with virchowian leprosy, and found proliferative 
glomerulonephritis in 13 of them. GROVER et al.19, in a study with 
54 renal biopsies found 12 cases (22.2%) of diffuse proliferative 
glomerulonephritis (11 virchowian and one tuberculoid). They also 
found two cases of rapidly progressive glomerulonephritis, with acute 
kidney injury. Membranous nephropathy was found in 17 cases (31.5%). 
PHADNIS et al.42 performed 50 renal biopsies and identified membranous 
nephropathy in two cases and membranoproliferative glomerulonephritis 
in six cases, of whom 45 had the lepromatous form and had reactional 
state. Interstitial nephritis was observed in 10 patients and amyloidosis 
in one case. Chronic kidney disease caused by secondary amyloidosis 
has also been described in leprosy52 (Fig. 2).
TUBULOINTERSTITIAL LESION: Interstitial nephritis is one 
of the most common histological findings in leprosy12,20,37. This has been 
described in patients with lepromatous leprosy, and is present in more 
than 20% of cases19. It seems to be related to disease duration and the 
long-term treatment with nephrotoxic drugs26. 
The identification of specific lesions in leprosy is described as 
the presence of granulomas in renal interstitium, with evidence of 
mononuclear cells with vacuolized cytoplasm, without the presence 
of Hansen’s bacilli43,47. Epithelioid granuloma and the Hansen’s bacilli 
have already been detected in renal parenchyma38. The low incidence of 
granulomas in renal tissue is due to the fact that renal tissue presents a 
resistance to M. leprae or the fact that the bacteria has a low affinity to 
renal tissue42.
The occurrence of tubular dysfunction is frequent, varying from 25 to 
85% of cases, in both multibacillary and paucibacillary forms7,40. Urinary 
acidification defect has been described in 20 to 32% of patients, and 
urinary concentration defect in 85% of cases16,40. Renal tubular acidosis 
has also been described16,21,40.
CHRONIC KIDNEY DISEASE: Chronic kidney disease (CKD) 
has been reported as one of the causes of death in leprosy, mainly in the 
first studies of leprosy nephropathy5,28,36,43,. CKD is mainly caused by 
amyloidosis and is also more frequent in the virchowian form26,33,52. It has 
also been reported in patients with the tuberculoid form33. A correlation 
between the duration of the disease and the development of amyloidosis 
has not been observed26. A positive correlation was detected between 
the occurrence of erythema nodosum and secondary amyloidosis in 
leprosy15,32,33. Serum levels of amyloid protein A increases in erythema 
nodosum episodes and remains high for several months. LOMONTE et 
al.32 described the evolution of eight patients with leprosy who developed 
CKD and required renal replacement therapy.
DRUGS TOXICITY: Despite not being common, renal abnormalities 
due to leprosy specific treatment have been described. There are reports 
on acute tubular necrosis, interstitial nephritis and papillary necrosis 
causing acute kidney injury in leprosy7,15. 
Acute kidney injury can occur due to interstitial nephritis secondary 
to rifampicin use, which is more common with higher doses (900-
1200mg) than the usual (450-600mg)22. Dapsone can induce hemolysis 
and intravascular coagulation, which can lead to acute tubular necrosis54.
Fig. 2 - Kidney biopsy from a patient with leprosy and chronic kidney disease showing amyloid 
deposits (A), H&E, x200; glomeruli without mesangial proliferation, with amyloid deposit 
in mesangium, H&E, x400; amyloid deposit, H&E x200; tubules without abnormalities, 
H&E x200. Reprinted from Silva Junior et al. Rev Soc Bras Med Trop. 2010;43:474-6.52
Fig. 1 - Pathophysiology of renal involvement in leprosy. AKI = acute kidney injury; CKD 
= chronic kidney disease.
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TREATMENT: Leprosy treatment encompasses specific therapy 
to overturn M. leprae, avoid immunological complications and 
prevent physical deformities, simultaneously promoting physical and 
psychosocial rehabilitation. Additionally, health authority notification 
is mandatory35. WHO-standardized leprosy therapy includes rifampicin, 
dapsone and clofazimine. Prednisone (1 to 2 mg/kg/day) and non-
steroidal anti-inflammatory drugs (NSAI) may be used to control acute 
immunological episodes. Erythema nodosum leprosum may sometimes 
have a protracted course (months, or years) and is usually treated with 
NSAI, steroids, thalidomide, clofazimine and pentoxiphyline. It must be 
kept in mind that all are potentially nephrotoxic. Hemodialysis or kidney 
transplant are alternatives in treating leprosy ESRD. Post-transplant 
immunosuppression apparently does not modify leprosy response to 
drugs. However, acute transitory deterioration of its course has been 
reported4.
CONCLUSION
Renal involvement is an important complication in leprosy, which 
should be investigated in every patient. Multibacillary status seems to 
be the main risk factor for kidney dysfunction in this disease. Different 
kinds of glomerulopathy have been described in association with leprosy. 
Specific treatment seems to impact on renal function improvement. 
RESUMO
Nefropatia da hanseníase: revisão dos aspectos clínicos e 
histopatológicos
A hanseníase é doença crônica causada pelo Mycobacterium leprae, 
altamente incapacitante e com envolvimento sistêmico em alguns casos. 
O envolvimento renal tem sido relatado em todas as formas da doença, 
sendo mais frequente nas formas multibacilares. A apresentação clínica é 
variável e determinada pela reação do sistema imunológico do hospedeiro 
ao bacilo. Durante o curso da doença podem ocorrer os chamados estados 
reacionais, nos quais o sistema imune reage contra o bacilo, exacerbando 
as manifestações clínicas. Diferentes lesões renais tem sido descritas na 
hanseníase, incluindo glomerulonefrites, nefrite intersticial, amiloidose 
secundária e pielonefrite. O mecanismo exato que leva à glomerulonefrite 
na hanseníase ainda não está completamente esclarecido. O tratamento da 
hanseníase inclui o uso de rifampicina, dapsona e clofazimina. Prednisona 
e antiinflamatórios não-hormonais podem ser usados no controle dos 
episódios imunológicos agudos.
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